Clinical pharmacology research for promoting individualized cancer chemotherapy

Hiroyuki Watanabe, Mayako Uchida, Satohiro Masuda

研究成果: ジャーナルへの寄稿評論記事

抄録

Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and e‹cacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.

元の言語英語
ページ(範囲)901-909
ページ数9
ジャーナルYakugaku Zasshi
139
発行部数6
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Clinical Pharmacology
aprepitant
Antiemetics
Drug Therapy
Research
Neoplasms
Neurokinin-1 Receptor Antagonists
Mantle-Cell Lymphoma
Receptors, Serotonin, 5-HT3
Quality of Health Care
Hematopoietic Stem Cell Transplantation
Drug-Related Side Effects and Adverse Reactions
Intravenous Injections
Nausea
Dexamethasone
Vomiting
Guidelines
Safety
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

これを引用

Clinical pharmacology research for promoting individualized cancer chemotherapy. / Watanabe, Hiroyuki; Uchida, Mayako; Masuda, Satohiro.

:: Yakugaku Zasshi, 巻 139, 番号 6, 01.01.2019, p. 901-909.

研究成果: ジャーナルへの寄稿評論記事

Watanabe, Hiroyuki ; Uchida, Mayako ; Masuda, Satohiro. / Clinical pharmacology research for promoting individualized cancer chemotherapy. :: Yakugaku Zasshi. 2019 ; 巻 139, 番号 6. pp. 901-909.
@article{fb6ebc6faa4747febb34a50a33a7a2e0,
title = "Clinical pharmacology research for promoting individualized cancer chemotherapy",
abstract = "Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and e‹cacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.",
author = "Hiroyuki Watanabe and Mayako Uchida and Satohiro Masuda",
year = "2019",
month = "1",
day = "1",
doi = "10.1248/yakushi.18-00213-1",
language = "English",
volume = "139",
pages = "901--909",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "公益社団法人 日本薬学会",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacology research for promoting individualized cancer chemotherapy

AU - Watanabe, Hiroyuki

AU - Uchida, Mayako

AU - Masuda, Satohiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and e‹cacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.

AB - Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and e‹cacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85067108982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067108982&partnerID=8YFLogxK

U2 - 10.1248/yakushi.18-00213-1

DO - 10.1248/yakushi.18-00213-1

M3 - Review article

C2 - 31155534

AN - SCOPUS:85067108982

VL - 139

SP - 901

EP - 909

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 6

ER -